Praxis Precision Medicines (PRAX) Could Be 56% Below Fair Value After FDA Priority Review

Praxis Precision Medicines (PRAX) is drawing fresh attention after the FDA placed its lead epilepsy candidate Relutrigine under priority review, with a decision expected by 27 December 2026.

Recent trading shows how sensitive Praxis Precision Medicines has become to regulatory milestones, with a 1-day share price return of 1.53% and a 90-day share price decline of 21.06% sitting alongside a 1-year total shareholder return of 65.24%. This suggests long-term holders have still seen strong gains as sentiment swings around the Relutrigine review story.

Scan other biotech stories riding similar FDA momentum by checking our curated list of 38 healthcare AI stocks alongside Praxis Precision Medicines.

The science around Relutrigine gives Praxis Precision Medicines a compelling story. After the recent share move and mixed shorter term returns, the harder question is whether that story is already fully reflected in the price.

Most Popular Narrative: 56% Undervalued

Praxis Precision Medicines closed at $284.79, while the most followed valuation narrative places fair value at $643.06. This uses a 7.4% discount rate and long term earnings assumptions to bridge the gap between today’s price and potential future cash generation.

Multiple late stage epilepsy programs, including vormatrigine and relutrigine with breakthrough designation in severe genetic epilepsies, create a portfolio effect in a growing CNS innovation cycle. This increases the probability of multiple approvals and a step change in total company earnings over the back half of the decade.

See why 8 investors see Praxis Precision Medicines as 56% undervalued.

Result: Fair Value of $643.06 (UNDERVALUED)

Still, the story around Praxis Precision Medicines can change quickly if key late stage epilepsy trials disappoint or if essential tremor uptake lags behind expectations.

Find out about the key risks to this Praxis Precision Medicines narrative.

Next Steps

Mixed sentiment runs through this Praxis Precision Medicines story, so treat it as a prompt to move fast: review the numbers, weigh both the risks and the potential upside, then decide whether the balance suits your own approach by checking the 2 key rewards and 1 important warning sign.

Looking for more Praxis Precision Medicines investment ideas?

If you stop your research with Praxis Precision Medicines, you risk missing opportunities where quality, price, and risk line up even more cleanly for your portfolio.

• Target resilient balance sheets and steady fundamentals by scanning the list of solid balance sheet and fundamentals (24 results) that keep financial risk in check.
• Hunt for quality at a discount by running through the 34 high quality undervalued stocks that pair fundamentals with prices some investors may be overlooking.
• Prioritise stability and lower volatility potential by reviewing the 31 resilient stocks with low risk scores that score well on resilience and downside protection.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com